Recent progress in developing of thrombolytic agents for ischemic stroke / 生物工程学报
Chinese Journal of Biotechnology
; (12): 2029-2039, 2020.
Article
in Zh
| WPRIM
| ID: wpr-878463
Responsible library:
WPRO
ABSTRACT
Ischemic stroke is a major health crisis causing high mortality and morbidity. The key treatment relies on the rapid intervention to dissolve thrombus, to reduce bleeding side effect and re-canalize clotted blood vessels using clot lysis drugs. Tissue plasminogen activator (tPA) is the only FDA-approved drug for ischemic stroke, but it has many limitations in clinical use. In recent years, the development of thrombolytic drugs and treatment strategies based on tPA has been progressed rapidly. Here we review the recent progress in this field, including the contributions from us and others, to promote the future development of novel thrombolytic drugs.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Research
/
Thrombolytic Therapy
/
Brain Ischemia
/
Tissue Plasminogen Activator
/
Stroke
/
Fibrinolytic Agents
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Biotechnology
Year:
2020
Document type:
Article